Breaking News

IBJ 08.14

Startup has rare disease in its sights.


Read more

Development Milestone

The company’s lead drug candidate has been accepted for further development by the National Institutes of Health.


Read more

Update 05.15

Chondrial Therapeutics is pleased to announce several development milestones.


Read more

IBJ 08.14

More patients help drug firms pass ‘valley of death'.


Read more

Technologies We Use


machinery


Advanced Technology

Chondrial Therapeutics has developed a mitochondrial protein replacement therapy for FRDA based on cell penetrant technology that can also serve as a platform technology for other mitochondrial disorders.



machinery


Published Proof of Principle

We have published proof of principle for replacing Frataxin protein in FRDA knockout animals and continue to develop further proof of concept with our targeted lead compound. Frataxin knockout mice live significantly longer with TAT-Frataxin fusion protein injections because heart and neurologic function, growth, and biochemistry are improved.


The Platform

Chondrial Therapeutics was formed to commercialize a proprietary protein replacement platform for mitochondrial diseases. This fusion protein platform was developed by Dr. Mark Payne who currently serves as the Chief Scientific Officer. Our focus is on Orphan diseases and Friedreich's Ataxia is our initial target.
Chondrial Therapeutics is actively seeking partnerships with pharmaceutical and biotechnology companies for its lead drug candidate for Friedreich’s Ataxia. Contact us to learn more.